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Abstract 
Cutaneous adverse drug reactions (CADRs) in patients with psychotropic drugs are common. 
Large studies on the relevant drugs and other risk factors are still scarce. 
594 cases of severe CADRs (“cases”) were compared with 8085 cases of other adverse drug 
reactions (“non-cases”) documented in a pharmacovigilance program in psychiatry (AMSP) from 
1993 to 2014. Logistic regression was carried out to determine risk factors and between-drug 
differences. 
CADRs were relatively more prevalent in patients treated with clomipramine, maprotiline, car- 
bamazepine, lamotrigine, acamprosate, clomethiazole and disulﬁram as well as with antide- 
pressants and anticonvulsants as drug classes ( p < 0.01). For these drugs, signiﬁcantly more 
women were found in patients using maprotiline, lamotrigine (not carbamazepine) and in the 
groups of antidepressants, tricyclics and anticonvulsants ( p < 0.01). Women were more vulner- 
able to CADRs (67% in cases and 56% in non-cases, p < 0.01). The signiﬁcantly higher rate of 
CADRs in women was mainly observed under age of 50 years, i.e. during female reproductive 
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years. In a multivariate logistic regression, female sex, the diagnostic group ICD F1 (substance 
abuse), maprotiline, carbamazepine, lamotrigine and clomethiazole were identiﬁed as risk fac- 
tors of CADRs. 
The case/non-case approach allowed to identify risk factors based on empirical data rather 
than experts’ evaluations. The new ﬁndings of substance abuse and clomethiazole as risk fac- 
tors for CADRs have to be conﬁrmed in further studies. Since CADRs can be life-threatening, it 
is important to be aware of risk factors, especially women during their reproductive period and 
with lamotrigine treatment. 
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC 
BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
1. Introduction 
Although the true incidence of adverse drug reactions 
(ADRs) is difﬁcult to determine, there is evidence that cu- 
taneous adverse drug reactions (CADRs) are among the most 
frequently observed adverse reactions to drugs ( Svensson 
et al., 2001 ). CADRs account for 10–20% of all reported 
ADRs ( Faich et al., 1987; van der Linden et al., 1998 ). 
These reactions may range from mildly discomforting ex- 
anthematous skin rashes to severe, life-threatening event 
like toxic epidermal necrolysis (TEN). The most severe and 
life-threatening types of CADRs consist of erythema mul- 
tiforme, urticaria, drug-induced hypersensitivity syndrome 
(DIHS) also referred to as drug reaction with eosinophilia 
and systemic symptoms (DRESS), and epidermal necrolysis - 
including Stevens-Johnson syndrome (SJS) and TEN ( Mitkov 
et al., 2014 ). 
In hospitalized patients, the incidence of CADRs ranges 
from 1% to 3% ( Arndt and Jick, 1976; Bigby et al., 1986 ), 
whereas the incidence of CADRs in patients taking psy- 
chotropic medications has been estimated as being approx- 
imately 2–5% ( Kimyai-Asadi et al., 1999 ). Due to possibly 
higher incidence of CADRs to psychotropic medications and 
potentially life-threatening reactions, it is clinically impor- 
tant to investigate cause and risk factors of CADRs to psy- 
chotropic medications. 
The causality assessment varies among reported studies 
and is limited by the ethical constraints of re-challenging 
patients with a drug that may evoke a life-threatening or 
seriously disabling reaction ( Svensson et al., 2001 ). Some 
risk factors, including female sex ( Bigby et al., 1986; Naldi 
et al., 1999; Fattinger et al., 2000; Alvestad et al., 2007; 
Wang et al., 2012 ), greater age ( Naldi et al., 1999; Warnock 
and Morris, 2002 ) and HLA-B ∗5801 and HLA-A ∗3101 subtype 
( McCormack et al., 2011 ) have been identiﬁed to be asso- 
ciated with CADRs. Despite of the high clinical relevance of 
CADRs, large scale studies identifying drugs prone to such 
effects, along with predictive risk factors are still rare. 
In this paper we analyzed the ADR data provided by the 
international Drug Safety Program in Psychiatry (Arzneimit- 
telsicherheit in der Psychiatrie, AMSP). The previous study 
of Lange-Asschenfeldt et al. (2009) with AMSP data from 
1993–2005 about CADRs had its focus on the reported in- 
cidence rates of severe CADRs to psychiatric drugs and was 
based on probability ratings of causality by experts ( Lange- 
Asschenfeldt et al., 2009 ). In this previous study, there 
were 214 cases of severe CADRs of psychotropic drugs in- 
cluding mood stabilizing anticonvulsants. Exanthems consti- 
tuted the majority of the recorded severe CADRs. The most 
common symptom was pruritus (50%), followed by edema 
(12%). The median clinical latency was below 10 days for 
all subtypes. Life-threatening CADRs amounted to 3% of the 
CADR cases. Immediate drug discontinuation was the direct 
measure in the vast majority of cases (about 95%). Drug 
treatment involved antihistamine (about 50%) and steroids 
(35.0%). 
In the present study we analyzed a larger dataset from 
1993–2014. Speciﬁcally, we aimed to identify new possible 
causes and risk factors through a case control design and 
multivariate regression. Thus we applied an empirical ap- 
proach that allows us to be as independent of experts’ deci- 
sion as possible. A previous report in the literature has sug- 
gested that women in their reproductive years have a higher 
incidence rate of CADRs than men because of their more 
reactive immune system ( Alvestad et al., 2007 ). There- 
fore, our study addressed the questions of (1) the extent 
to which the relative CADR rates differ between males and 
females; (2) the inﬂuence of age; (3) potential between- 
drug differences; and (4) risk factors that may predict 
CADRs. 
2. Experimental procedures 
2.1. Data source 
The adverse drug reaction (ADR) dataset in the present 
study was collected through AMSP since 1993. AMSP is an 
ongoing international multicenter drug safety surveillance 
program that systematically collects data on psychophar- 
macotherapy and ADRs from more than 100 psychiatric hos- 
pitals in the German speaking countries (Germany, Austria 
and Switzerland). The underlying method of the project 
has been described in detail by various previous publica- 
tions ( Engel et al., 2004; Grohmann et al., 2004; Lange- 
Asschenfeldt et al., 2009; Friedrich et al., 2016 ): data on 
severe ADRs due to psychopharmacological treatment are 
systematically assessed by the participating hospitals. ADRs 
are regarded as “severe” when causing signiﬁcant impact on 
the course of treatment (e.g., life-threatening or seriously 
endangering health) or on the patients’ everyday function- 
ing. The AMSP protocol provides speciﬁc guidelines for the 
assessment of ADRs in relation to respective organ system, 
for example, CADRs is classiﬁed as severe when the whole 
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body or more than one body part is affected ( Grohmann et 
al., 2014 ). For each adverse event, a detailed description 
is documented along with the basic demographic, psychi- 
atric and somatic data (including all diagnoses). All cases 
are reviewed by a senior psychiatrist of each hospital and 
discussed thereafter at case conferences. The probability 
for the ADR to be caused by a speciﬁc drug is rated as fol- 
lows ( Grohmann et al., 2004 ). 
Possible : ADR unknown or alternative explanation more 
likely. 
Probable : ADR known for drug in question and time- 
course and dosage in accordance with previous experience; 
alternative explanation less likely. 
Deﬁnite : the same as “probable” together with reappear- 
ance after re-exposure with drug in question. 
Questionable : questionable or not sufﬁciently docu- 
mented. 
In addition, drug use was collected by all participating 
hospitals on two pre-speciﬁed reference days every year for 
all inpatients. This prescription dataset was not used in this 
study. 
Our study included all ADR cases from 1993 to 2014 with 
a probability rating of “deﬁnite”, “probable”, or “possible”
with focus being laid on all concomitant drugs. By applying 
this method, our case control study is not limited by expert 
evaluations. 
The AMSP drug surveillance program was approved by the 
leading boards of each participating institute prior to im- 
plementation, and the Ethics Committee of the University 
of Munich formally approved evaluations based on the AMSP 
databank. 
2.2. Study design 
A nested case control design, i.e. case/non-case approach 
( Moore et al., 1997 ) was used to identify new possible 
causes and risk factors of CADRs. CADRs were deﬁned as 
cases, and all other ADRs were regarded as non-cases. Cases 
and non-cases were both derived from the ADR dataset of 
AMSP as described above. Reports were only included when 
data were complete and patients were 18 years or older. 
The ADR dataset under investigation was comprised of 9592 
ADR reports. Of these, 474 cases were excluded because of 
incomplete information, and 439 cases because of skin re- 
lated ADRs - like edema, acne and hair loss - which were 
not classiﬁed as CADRs for the purpose of this study. Hence, 
our study was conducted with 8679 ADR reports, represent- 
ing 90.48% of the total available ADR reports. We identiﬁed 
594 (6.84%) CADR cases and 8085 non-cases (93.16%). Re- 
porting odds ratio (ROR) of ADR is the ratio of the report- 
ing odd of the association between the CADR and the expo- 
sure of the interest. ROR is a measure of disproportionality 
in case/non-case approach ( van Puijenbroek et al., 2002; 
Rothman et al., 2004 ). The ROR and its conﬁdence intervals 
were computed as described in Moore et al. (1997) . RORs 
whose conﬁdence interval did not include 1 were consid- 
ered as signiﬁcantly different from 1. 
If the ROR is greater than 1 as deﬁned above, then it 
can be interpreted as indicating an association between 
the exposure and reporting of the reaction of interest. This 
method can be regarded as a variant of the database nested 
case-control method ( Kramer et al., 1988 ; Strom et al., 
1994 ). Exposure to a certain drug or drug class was deﬁned 
as the presence of the drug or drug class of interest in a 
report, independently of whether or not the drug or drug 
class was suspected of causing the reaction. In addition, di- 
agnostic groups and gender were investigated by means of 
the same method. 
In the next step, we calculated and compared the ratios 
of female to male among different age groups for cases and 
non-cases. 
2.3. Data analysis/statistics 
In case/non-case approach, Student’s t test was performed 
to assess the signiﬁcance of differences in the mean of con- 
tinuous variables between cases and non-cases. Differences 
in the proportions of the characteristics between cases 
and non-cases were tested for signiﬁcance with χ2 test or 
Fisher’s exact test where appropriate. The strength of as- 
sociation between the exposure of interest and CADR was 
expressed as ROR with 95% conﬁdence intervals. First, we 
conducted standard univariate analysis of ROR for several 
factors. Subsequently, these RORs were adjusted for age, 
reporting time period, hospital, number of diagnoses and 
number of concomitant drugs by means of multivariate lo- 
gistic regression analysis. Finally, 95% conﬁdence intervals 
of the resulting female-male ratios (by age groups) were 
calculated and compared between cases and non-cases. 
All statistical calculations were performed using SAS soft- 
ware (Statistical Analysis System, version 9.3). 
3. Results 
The sample under investigation was comprised of 594 CADR 
cases and 8085 non-cases exhibiting other ADRs. Table 1 
shows the basic characteristics of cases versus non-cases. 
There were signiﬁcantly more female patients ( p < 0.001) 
among the cases compared to the non-cases. Despite the 
differences in the sample composition, there was no sig- 
niﬁcant difference in terms of mean age or mean number 
of concomitant medication between cases and non-cases. 
Moreover, no signiﬁcant difference showed up between 
cases and non-cases regarding monotherapy, combination 
therapy and polypharmacy. To determine if the reporting 
period might play a role, we divided the observation in- 
terval into three periods: 1993–2000, 2001–2007 and 2008–
2014. Interestingly, there were signiﬁcantly fewer cases re- 
ported than non-cases during the most recent time period 
( p < 0.001). 
Table 2 shows the diagnostic groups (according to ICD 10) 
for cases and non-cases. Mental and behavioral disorders 
due to psychoactive substance use (ROR 2.64; 95% CI 2.21–
3.15), mood [affective] disorders (ROR 1.43; 95% CI 1.21–
1.69) and disorders of adult personality and behavior (ROR 
1.47; 95% CI 1.11–1.94) were the diagnostic groups signiﬁ- 
cantly more involved in cases. 
Table 3 shows the drug classes for cases and non-cases. 
We found a signiﬁcant increase of RORs under antidepres- 
sants (AD: ROR 1.25; 95% CI 1.04–1.49), tricyclic antide- 
pressants (TCA: ROR 1.43; 95% CI 1.14–1.79), antiepileptic 
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Table 1 Characteristics of cases and non-cases. 
Cases Non-cases P value 
N = 594 N = 8085 
Mean age ( ± S.D.) 47.12 ( ± 16.19) 48.45 ( ± 18.89) NS 
Female ∗∗ 395 (66.50%) 4,521 (55.92%) < 0.001 
Mean No. of medication ( ± S.D.) 3.88 ( ± 2.23) 3.97 ( ± 2.50) NS 
Medication 
Monotherapy 135 (22.73%) 1634 (20.21%) NS 
Combination therapy 177 (29.80%) 2426 (30.01%) NS 
Polypharmacy 282 (47.47%) 4025 (49.78%) NS 
Reporting year 
1993–2000 138 (23.23%) 1462 (18.08%) NS 
2001–2007 286 (48.15%) 3478 (43.02%) NS 
2008–2014 ∗∗ 170 (28.62%) 3145 (38.90%) < 0.001 
Monotherapy: one psychotropic drug; Combination therapy: two psychotropic drugs; Polyphar- 
macy: three or more psychotropic drugs. 
∗ p value < 0.05, NS: not signiﬁcant. 
∗∗ p value < 0.01. 
Table 2 Cases and non-cases per diagnosis group. 
Diagnosis group ICD10 ∗: deﬁnition Cases Non-cases ROR 
N = 594 N = 8085 (95% CI) 
F00-F09: organic, including symptomatic, mental disorders 46 (7.74%) 1045 (12.93%) 0.57 (0.42–0.77) 
F10-F19 ∗∗: mental and behavioral disorders due to psychoactive 
substance use 
212 (35.69%) 1406 (17.39%) 2.64 (2.21–3.15) 
F20-F29: schizophrenia, schizotypal and delusional disorders 137 (23.06%) 3351 (41.45%) 0.42 (0.35–0.52) 
F30-F39 ∗∗: mood [affective] disorders 300 (50.51%) 3372 (41.71%) 1.43 (1.21–1.69) 
F40-F48: neurotic, stress-related and somatoform disorders 73 (12.29%) 818 (10.12%) 1.25 (0.96–1.61) 
F50-F59: behavioral syndromes associated with physiological 
disturbances and physical factors 
6 (1.01%) 114 (1.41%) 0.71 (0.31–1.63) 
F60-F69 ∗∗: disorders of adult personality and behavior 60 (10.10%) 575 (7.11%) 1.47 (1.11–1.94) 
F70-F79: mental retardation 11 (1.85%) 208 (2.57%) 0.72 (0.39–1.32) 
The total is higher than 100% since there could be multiple diagnoses per patient. 
∗ With minimum of three cases of CADR. 
∗∗ ROR signiﬁcantly greater than 1. 
drugs (AEP: ROR 3.30; 95% CI 2.79–3.90) and other psy- 
chotropic drugs (including acamprosate, clomethiazole and 
disulﬁram; ROR 6.13; 95% CI 3.99–9.42). 
Table 4 compares cases and non-cases for single drugs. 
Comparing CADRs to the other ADRs, clomipramine (ROR 
1.86; 95% CI 1.15–3.03), maprotiline (ROR 1.22; 95% CI 2.26–
4.19), carbamazepine (ROR 6.83; 95% CI 5.52–8.44), lam- 
otrigine (ROR 4.14; 95% CI 3.01–5.68), clomethiazole (ROR 
6.77 95% CI 4.13–11.09), acamprosate (ROR 4.56; 95% CI 
1.23–16.87; only three CADRs) and disulﬁram (ROR 4.10; 95% 
CI 1.13–14.94; only three CADRs) showed signiﬁcantly more 
cases than non-cases. 
Table 5 shows the percentage of females for relevant drug 
classes and for those drugs that were related to increased 
numbers of cases ( Table 4 ). AD, TCA, AEP, maprotiline and 
lamotrigine were signiﬁcantly more often prescribed in fe- 
males among cases than among non-cases. 
Our multivariate logistic regression model included the 
following variables: gender, age, time period, reporting 
hospital, number of diagnoses and number of concomitant 
drugs along with variables for diagnostic groups and medi- 
cations. This model identiﬁed female sex, diagnoses F10-19 
(substance abuse), maprotiline, carbamazepine, lamotrig- 
ine and clomethiazole as signiﬁcant risk factors of CADRs 
( Table 6 ). 
The time-to-onset ( Fig. 1 ) had a median value of 6 days 
in cases and 10 days in non-cases. The mean value was 17 
( ± S.D. 127.4) days in the cases and 59 ( ± S.D. 301.8) days 
in the non-cases (not signiﬁcant). 
Fig. 2 shows the female-male ratios in CADRs stratiﬁed 
by age groups compared with non-cases. For the age groups 
18–30, 31–40 and 41–50 years, female-male ratios were sig- 
niﬁcantly higher in CADRs than in non-cases. This signiﬁcant 
difference was not present in the higher age groups 51–60 
and 61–70. The mean relative female-male ratio was 1.7 in 
the age group 18–50 and 1.24 in the age group 51–70. 
4. Discussion 
In this case-control study, 594 patients suffering from se- 
vere CADRs (cases) were compared with 8085 patients suf- 
fering from other severe ADRs (non-cases) as documented in 
a large pharmacovigilance program. The CADR cases were 
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Table 3 Cases and non-cases per drug class. 
Drug 
class ∗
Cases Non-cases ROR 
N = 594 N = 8085 (95% CI) 
AD ∗∗ 411 (69.19%) 5,197 (64.28%) 1.25 (1.04–1.49) 
TCAs ∗∗ 98 (16.50%) 980 (12.12%) 1.43 (1.14–1.79) 
SSRIs 132 (22.22%) 1658 (20.51%) 1.11 (0.91–1.35) 
SNRIs 67 (11.28%) 995 (12.31%) 0.91 (0.70–1.18) 
NaSSAs 67 (11.28%) 1015 (12.55%) 0.89 (0.68–1.15) 
MAOIs 13 (2.19%) 116 (1.43%) 1.54 (0.86–2.74) 
OADs 34 (5.72%) 442 (5.47%) 1.05 (0.73–1.50) 
AEP ∗∗ 285 (47.98%) 1766 (21.84%) 3.30 (2.79–3.90) 
Lithium 47 (7.91%) 656 (8.11%) 0.97 (0.72–1.33) 
Anti-parkinson drugs 43 (7.24%) 690 (8.53%) 0.84 (0.61–1.15) 
Hypnotics 74 (12.46%) 889 (11.00%) 1.15 (0.89–1.48) 
BZDs 200 (33.67%) 2867 (35.46%) 0.92 (0.78–1.10) 
Z-drugs 43 (7.24%) 641 (7.93%) 0.91 (0.66–1.25) 
Antipsychotics 458 (77.10%) 9385 (116.08%) 0.66 (0.59–0.75) 
Typical antipsychotics 102 (17.17%) 2126 (26.30%) 0.76 (0.66–0.89) 
Atypical antipsychotics 234 (39.39%) 5603 (69.30%) 0.29 (0.24–0.34) 
Antidementia drugs 14 (2.36%) 252 (3.12%) 0.75 (0.44–1.29) 
Tranquillizers 185 (31.14%) 2666 (32.97%) 0.92 (0.77–1.10) 
Others ∗∗ 31 (5.22%) 72 (0.89%) 6.13 (3.99–9.42) 
AEP: antiepileptic; AD: antidepressant; TCAs: tricyclic antidepressants; SSRIs: selective serotonin reuptake inhibitors; 
SNRIs: selective Serotonin–norepinephrine reuptake inhibitors; NaSSAs: noradrenergic and speciﬁc serotonergic an- 
tidepressants; MAOIs: monoamine oxidase inhibitors; OADs: other ADs, including agomelatin, bupoprion, nefazodone, 
reboxetine, tianeptine and trazodone; BZDs: benzodiazepine derivatives; Z-drugs: zopiclone, zopidem and zaleplon; 
others: acamprosate, clomethiazole, disulﬁram. 
∗ With a minimum of three cases of CADR, 
∗∗ ROR signiﬁcantly greater than 1. 
Table 4 Cases and non-cases per relevant single drug. 
Medication ∗ Cases (%) Non-cases (%) ROR 
N = 594 N = 8085 (95% CI) 
TCA 
Amitriptyline 15 (2.53%) 248 (3.07%) 0.82 (0.48–1.39) 
Clomipramine ∗∗ 19 (3.20%) 141 (1.74%) 1.86 (1.15–3.03) 
Dibenzepine 3 (0.51%) 21 (0.26%) 1.95 (0.58–6.56) 
Doxepine 15 (2.53%) 154 (1.90%) 1.34 (0.78–2.28) 
Maprotiline ∗∗ 12 (2.02%) 73 (0.90%) 1.22 (2.26–4.19) 
Nortriptyline 6 (1.01%) 66 (0.82%) 1.24 (0.54–2.87) 
Trimipramine 24 (4.04%) 224 (2.77%) 1.48 (0.96–2.27) 
AEP 
Carbamazepine ∗∗ 149 (25.08%) 378 (4.68%) 6.83 (5.52–8.44) 
Clonazepam 5 (0.84%) 99 (1.22%) 0.69 (0.28–1.69) 
Gabapentin 7 (1.18%) 47 (0.58%) 2.04 (0.92–4.53) 
Lamotrigine ∗∗ 53 (8.92%) 187 (2.31%) 4.14 (3.01–5.68) 
Oxcarbazepine 10 (1.68%) 93 (1.15%) 1.47 (0.76–2.84) 
Pregabalin 7 (1.18%) 168 (2.08%) 0.56 (0.26–1.20) 
Valproate 47 (7.91%) 674 (8.34%) 0.95 (0.69–1.29) 
Others 
Acamprosate ∗∗ 3 (0.51%) 9 (0.11%) 4.56 (1.23–16.87) 
Clomethiazole ∗∗ 24 (4.04%) 50 (0.62%) 6.77 (4.13–11.09) 
Disulﬁram ∗∗ 3 (0.51%) 10 (0.12%) 4.10 (1.13–14.94) 
TCAs: tricyclic antidepressants; AEP: antiepileptic; Others: acamprosate, clomethiazole, disulﬁram. 
∗ With a minimum of three cases of CADRs from signiﬁcant drug groups in Table 4 , maprotiline is classiﬁed here as 
TCA. 
∗∗ ROR signiﬁcantly greater than 1. 
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Table 5 Percentage of females in cases and non-cases per relevant prescribed drug class and single drug. 
Cases (%) Non-cases (%) P value 
N = 594 N = 8085 
Female (%) ∗∗ 395 (66.50%) 4521 (55.92%) < 0.001 
AD ∗∗ 74.94% 67.73% 0.0025 
TCA ∗∗ 79.59% 60.39% 0.0078 
Clomipramine 73.68% 61.41% NS 
Maprotiline ∗∗ 75.00% 66.22% 0.0055 
AEP ∗∗ 64.91% 53.79% < 0.001 
Carbamazepine 54.36% 55.82% NS 
Lamotrigine ∗∗ 88.68% 64.71% < 0.001 
Others 22.58% 34.29% NS 
Acamprosate 33.33% 33.33% NS 
Clomethiazole 16.67% 30.00% NS 
Disulﬁram 33.33% 20.00% NS 
AD: antidepressants; TCAs: tricyclic antidepressants; AEP: antiepileptics; Others: acamprosate, clomethiazole, 
disulﬁram. 
∗ p value < 0.05. 
∗∗ p value < 0.01. 
Table 6 Factors correlated with CADRs according to logistic regression. 
Cases (%) Non-cases (%) Unadjusted ROR (95% CI) Adjusted a ROR (95% CI) P value 
N = 594 N = 8085 
Female ∗∗ 395 (66.50%) 4521 (55.92%) 1.57 (1.31–1.87) 1.75 (1.43–2.13) < 0.001 
Diagnosis group 
F00-F09 46 (7.74%) 1045 (12.93%) 0.57 (0.42–0.77) 0.53 (0.32–0.87) 0.0127 
F10-F19 ∗∗ 212 (35.69%) 1406 (17.39%) 2.64 (2.21–3.15) 1.68 (1.15–2.45) 0.0073 
F20-F29 137 (23.06%) 3351 (41.45%) 0.42 (0.35–0.52) 0.38 (0.26–0.56) < 0.001 
F30-F39 300 (50.51%) 3372 (41.71%) 1.43 (1.21–1.69) 0.80 (0.56–1.15) NS 
F40-F49 73 (12.29%) 818 (10.12%) 1.25 (0.96–1.61) 0.89 (0.60–1.33) NS 
F50-F59 6 (1.01%) 114 (1.41%) 0.71 (0.31–1.63) 0.48 (0.20–1.18) NS 
F60-F69 60 (10.10%) 575 (7.11%) 1.47 (1.11–1.94) 0.82 (0.54–1.25) NS 
F70-F79 11 (1.85%) 208 (2.57%) 0.72 (0.39–1.32) 0.60 (0.29–1.26) NS 
Medications 
Clomipramine 19 (3.20%) 141 (1.74%) 1.86 (1.15–3.03) 1.35 (0.79–2.32) NS 
Maprotiline ∗ 12 (2.02%) 73 (0.90%) 1.22 (2.26–4.19) 2.11 (1.09–4.10) 0.0270 
Carbamazepine ∗∗ 149 (25.08%) 378 (4.68%) 6.83 (5.52–8.44) 5.72 (4.45–7.37) < 0.001 
Lamotrigine ∗∗ 53 (8.92%) 187 (2.31%) 4.14 (3.01–5.68) 6.05 (4.20–8.72) < 0.001 
Acamprosate 3 (0.51%) 9 (0.11%) 4.56 (1.23–6.87) 2.70 (0.65–11.24) NS 
Clomethiazole ∗∗ 24 (4.04%) 50 (0.62%) 6.77 (4.13–1.09) 2.34 (1.27–4.33) 0.0066 
Disulﬁram 3 (0.51%) 10 (0.12%) 4.10 (1.13–4.94) 3.32(0.81–13.59) NS 
a adjustment was made for age, reporting years, reporting hospital, number of diagnosis and number of concomitant 
drugs. Adjusted R 2 of the regression model was 20.81%. 
∗ p value < 0.05 and ROR greater than 1. 
∗∗ p value < 0.01 and ROR greater than 1. 
6.8% of all ADR cases, suggesting that CADR was rather fre- 
quently associated with psychotropic drugs. In the most re- 
cent period from 2007 to 2014, the percentage of CADR 
cases was lower (5.1%). The case/non-case approach with a 
multivariate logistic regression analysis allowed us to iden- 
tify inﬂuencing factors without limited by experts’ opinions. 
4.1. Age/sex difference 
Greater age has been associated with CADRs in general 
( Naldi et al., 1999 ) or with CADRs to antidepressants 
( Warnock and Morris, 2002 ). In our case/non-case analysis, 
the result showed that there was no signiﬁcant difference 
of mean age between CADRs and other ADRs. This could 
be due to the nature of case/non-case analysis, since the 
case/non-case method compares different ADRs within the 
same dataset. Therefore, a risk factor generally associated 
to all ADRs cannot be found by this approach. 
The generally higher risk of women developing adverse 
drug reactions is described for various adverse drug re- 
actions ( Fattinger et al., 2000; Pirmohamed et al., 2004; 
Patel et al., 2007; Franconi and Campesi, 2014 ), but could 
not be found in all studies ( D’Incau et al., 2014 ). Regarding 
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Figure 1 Frequency of time-to-onset of ADRs in case and non-case. 
Figure 2 Female-male ratios of CADRs stratiﬁed by age groups. 
∗ age groups with female-male ratio signiﬁcantly greater than 1. 
CADRs, a sex difference with higher incidence in women in 
general ( Bigby et al., 1986; Naldi et al., 1999 ) or only for 
certain drug groups ( Alvestad et al., 2007; Lange- 
Asschenfeldt et al., 2009; Wang et al., 2012 ) was found, but 
could not be shown in other studies ( Li and Ma, 2006; Hirsch 
et al., 2006 ). Our results show that women (56%) predom- 
inated in non-cases, but the sex difference was more ap- 
parent in cases (67%). There were signiﬁcantly more female 
patients ( p < 0.001) in cases than non-cases, which clearly 
demonstrates that sex difference is particularly important 
for CADRs. 
4.2. Polypharmacy 
Between cases and non-cases, we did not ﬁnd signiﬁcant 
difference in terms of mean number of concomitant med- 
ication, proportion of monotherapy, combination therapy 
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and polypharmacy. In contrast, previous studies using differ- 
ent methods have identiﬁed polypharmacy as a risk factor 
for many clinically relevant ADRs ( Fattinger et al., 2000 ). 
The discrepancy could be due to the nature of the ap- 
proach, since case/non-case method compares different 
ADRs within one dataset. There are also contradicting ﬁnd- 
ings whether polypharmacy is a risk factor of CADRs to 
psychotropic drugs. It has been identiﬁed as risk factor of 
CADRs to antidepressants ( Warnock and Morris, 2002 ) and to 
mood stabilizers, especially the combination of lamotrigine 
and valproate ( Warnock and Morris, 2003 ), whereas it was 
not found for antiepileptics in another study ( Wang et al., 
2012 ). Further research regarding polypharmacy of differ- 
ent drug classes and combinations as risk factor of CADRs is 
needed. 
4.3. Reporting time period 
We divided the reporting years into three groups: 1993–
2000, 2001–2007 and 2008–2014. There was a signiﬁcant 
difference between reporting of cases and non-cases dur- 
ing 2008–2014 ( p < 0.01). During the latest time period, re- 
ports of CADRs dropped about 40% as compared to the sec- 
ond time period, while the reporting of other ADRs did 
not decrease. This indicates a decrease of CADR cases over 
time compared to other ADRs, presumably caused by differ- 
ent prescribing patterns with less frequent prescriptions of 
CADR related drugs ( Tables 3 and 4 ), e.g. lower prescription 
rate of carbamazepine ( Druschky et al., 2018 ) and tricyclic 
antidepressant drugs ( Stübner et al., 2018 ) in the more re- 
cent years. 
4.4. Time-to-onset 
The time period between initiation of drug treatment and 
the onset of ADRs (time-to-onset) is clinically important. 
We found an average time-to-onset of 17 days in cases and 
59 days in non-cases (not signiﬁcant). The median time-to- 
onset was 6 days in cases and 10 days in non-cases. CADRs 
appeared to occur slightly earlier than the rest of the ADRs. 
4.5. Medication 
There have been several studies on CADRs to psychotropic 
drugs, especially regarding antiepileptic and antidepres- 
sant drugs ( Warnock and Morris, 2002 , 2003; Alvestad et 
al., 2007; Amsterdam et al., 2009; Wang et al., 2012 ). In 
the present study, we found clomipramine, maprotiline (tri- 
cyclic antidepressants and also the overall group of antide- 
pressants), carbamazepine and lamotrigine (and antiepilep- 
tics in general) to be positively associated with CADRs. Our 
results are accordant with previous studies ( Warnock and 
Morris, 2002 , 2003; Alvestad et al., 2007; Wang et al., 2012 ). 
In addition, we found that acamprosate, clomethiazole and 
disulﬁram (and thus also the group of “other psychotropic 
drugs”) were signiﬁcantly more involved in CADR cases. It 
is remarkable that these three drugs prescribed preferably 
in alcohol abuse were associated with CADRs. These sub- 
stances are not only structurally different, but also used for 
very different therapeutic purposes, e.g. for the treatment 
of delirium (clomethiazole), as an anti-craving substance 
(acamprosate) or as withdrawal / aversion therapy (disul- 
ﬁram). This may indicate that the diagnosis itself (F1) could 
be the underlying risk factor. 
4.6. Diagnosis 
Consecutively, we examined the relationship between di- 
agnosis and CADRs. Interestingly, we found that F1 (men- 
tal and behavioral disorders due to psychoactive substance 
use), F3 (mood [affective] disorders) and F6 (disorders of 
adult personality and behavior) according to ICD 10 were 
more prevalent in patients with CADRs compared to other 
ADRs. To decide whether the diagnostic group or the re- 
spective medication was more relevant for CADRs, a logistic 
regression was performed (see below). 
4.7. Relation of medication, sex and age 
For drugs that were signiﬁcantly more involved in cases than 
non-cases, sex differences were calculated. Our analyses 
found signiﬁcant sex differences for tricyclic antidepres- 
sants, for antidepressant drugs generally, for antiepileptics 
generally and for lamotrigine (but not for carbamazepine). 
Consistently, previous studies from AMSP reported higher 
incidence of CADRs in woman using antiepileptic drugs 
( Lange-Asschenfeldt et al., 2009 ) and lamotrigine speciﬁ- 
cally ( Druschky et al., 2018 ). 
Remarkably, the relative rates of CADRs of female to male 
were larger than 1 in the age groups between 18 and 50. 
In contrast, there was no statistically signiﬁcant sex differ- 
ence in higher age groups. While in the reproductive age 
group there were 70% more women than men, in the higher 
age group there were only 24% more women. Female sex 
has been identiﬁed as a risk factor of CADR in many pre- 
vious publications ( Bigby et al., 1986; Naldi et al., 1999; 
Fattinger et al., 2000; Alvestad et al., 2007; Wang et al., 
2012 ), but only one previous study also showed that females 
are at higher risk of CADRs only during reproductive years 
( Alvestad et al., 2007 ). This interaction between age and 
sex might be explained with sex hormones during reproduc- 
tive years and their effects on the immune system. 
There are several known pathomechanisms for CADRs. 
Some are the result of non-immunological causes such as cu- 
mulative toxicity, photosensitivity or interaction with other 
drugs, while others are immune-mediated reactions such as 
allergic reactions ( Marzano et al., 2016 ). Women have been 
considered “immune-privileged” due to the sex hormones 
( Gieﬁng-Kröll, 2015 ). The female sex steroid hormones en- 
hance the innate immune responses in both physiological 
and pathological states, whereas androgens mainly suppress 
them ( Da Silva, 1999; Gieﬁng-Kröll, 2015 ). For example, re- 
sponses to various types of vaccination are often higher in 
women ( Cook, 2008 ) and a similar shift to female predom- 
inance is reported for asthma, atopic conditions and hay 
fever during reproductive years ( Shamssain and Shamsian, 
1999; Osman, 2003 ). It has been discussed that women lose 
their immunological “advantage” after menopause based 
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on epidemiological data, and hormone replacement ther- 
apy (HRT) shows beneﬁcial effects on the immune system 
( Gieﬁng-Kröll, 2015 ). 
4.8. Factors according to the multivariate logistic 
regression 
Our multivariate analysis demonstrated that sex (female), 
diagnostic group (F1 substance abuse), maprotiline, carba- 
mazepine and lamotrigine as well as clomethiazole were in- 
dependent risk factors in CADR cases with adjustment for 
age, reporting years, reporting hospital, diagnostic groups 
and medications. To our knowledge, we for the ﬁrst time 
demonstrated that substance abuse and clomethiazole were 
associated with CADRs after controlling for possibly con- 
founding factors. Previously, a report of toxic epidermal 
necrolysis as ADR of carbamazepine administration, heroin 
and alcohol abuse was published ( Petter and Haustein, 
1999 ). Furthermore, another case-control study identiﬁed 
alcohol abuse as the only risk factor for carbamazepine–
induced serious mucocutaneous adverse reactions using 
multivariate regression ( Bertulyte et al., 2014 ). Whether 
substance abuse (especially alcohol) alters immunity and 
subsequently increases susceptibility to CADRs needs to be 
further investigated. Consistently, a case of severe allergic 
reaction to clomethiazole has been reported ( Khan, 1976 ). 
However, the case report was discussed brieﬂy after that 
the allergic reaction might have been caused by the coloring 
agent tartrazine in the capsules of clomethiazole, not the 
drug itself ( Weeks, 1977 ), but another reply added one case 
report of allergic skin reaction to clomethiazole ( Halstead 
and Madden, 1976 ). Taken together, the new ﬁndings en- 
courage to further explore the underlying mechanisms of 
CADRs possibly caused by substance abuse or by clomethia- 
zole. 
4.9. Strength and limitation 
The method of case/non-case study has led to plausi- 
ble and novel results. The ADRs with their prescriptions 
were compared without taking the experts’ causality as- 
sessment (“imputation”) into account. Prejudice, which is 
unavoidable in imputation, e.g. due to technical informa- 
tion/package insert and to the state of literature, is elimi- 
nated to some extent. 
The ROR is identical to the odds ratio calculated from 
a case-control study that compares each drug to all other 
drugs ( Rothman et al., 2004 ). An advantage of using ROR is 
that non-selective underreporting of a drug or ADR does not 
essentially inﬂuence the ROR. Underreporting is inevitable 
in spontaneous reporting ADR datasets. It has been sug- 
gested that underreporting is more or less of the same mag- 
nitude for all drugs and other exposures. Hence, it is possi- 
ble to identify differences in adverse effects of drugs from 
comparison of their frequency within the same data source 
( Pierﬁtte et al., 1999 ). 
One of the disadvantages of the approach is that the asso- 
ciations in case/non-case study can be biased in some ways. 
The association of a drug and a single ADR in the analy- 
sis of spontaneous reports can be lessened if another re- 
action speciﬁc to the drug is widely reported ( Moore et al., 
1997 ). In our study, antipsychotics were underrepresented 
in CADRs ( Table 3 ). This could be due to the fact that an- 
tipsychotics have other ADRs in the foreground, such as ex- 
trapyramidal disorders or weight gain. On the other hand, 
very low incidence rates of CADRs of antipsychotics have 
also been reported previously ( Lange-Asschenfeldt et al., 
2009 ). 
Another problem occurs in the selection of cases from a 
spontaneous reporting database. In the AMSP study, drug 
monitors collect data on ADRs in association with psy- 
chopharmacological treatment that occurred within these 
hospitals. The cases are then reviewed by a senior doctor 
of each hospital and discussed thereafter at central case 
conference. We cannot rule out that CADRs have been de- 
tected more often than some other ADRs such as clinically 
relevant changes in laboratory values. On the other hand, a 
few CADR cases may have been missed because of the se- 
lection criteria based on experts’ decision that the CADR 
has to be related to the drug treatment. There could be 
uneven under-reporting among different drugs due to the 
possible unrecognition of the reaction as drug-related. To 
alleviate the issue, the present study included all the ADR 
cases with a probability rating of “possible ” or higher and all 
the concomitant drugs of ADR cases were analyzed regard- 
less of whether the drugs were imputed or not. Therefore, 
it is aligned with our goal of the evidence-based approach, 
since it is not limited only to the drugs imputed by experts. 
Nevertheless, in a spontaneous reporting system, the under- 
and selective reporting of ADRs is principally a serious prob- 
lem in quantifying ADRs in relation to drugs and other risk 
factors. 
4.10. Conclusion 
Regarding time-to-onset, the CADRs seem to occur earlier 
than other ADRs covered by the AMSP project: median 6 days 
versus 10 days. Particularly at the beginning of the treat- 
ment, CADR should be considered. 
Important risk factors of CADRs identiﬁed in this study 
are: female sex (especially during reproductive age pe- 
riod), diagnostic group F1 (substance abuse) and the drugs 
maprotiline, carbamazepine, lamotrigine and clomethia- 
zole. Since CADRs can be threatening, it is important to be 
aware of these risk factors. In contrast to maprotiline, car- 
bamazepine and clomethiazole, lamotrigine still plays a ma- 
jor role in psychiatric pharmacotherapy. Patients prescribed 
with lamotrigine, especially females, should be informed 
about CADRs and encouraged to observe themselves, and 
all recommended and widely followed precautionary mea- 
sures should be strictly followed, e.g. slow increase in dos- 
ing. In addition, this study indicates that substance abuse 
is an important risk factor for CADRs. So far, little atten- 
tion has been paid to substance abuse (diagnosis group F1), 
which apparently favors the likelihood of CADRs to different 
medications. 
By the case/non-case study with all prescriptions and re- 
lated ADRs, novel relationships could be found that need 
to be veriﬁed or falsiﬁed in further studies. In the present 
study, substance abuse and clomethiazole identiﬁed as risk 
factors of CADRs are such novel ﬁndings. 
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